Labcorp (NYSE:LH) Sees Neutral Rating and Price Target Increase by Piper Sandler

Font: Financial Modeling Prep  • Feb 24, 2026

• Piper Sandler adjusted Labcorp's (NYSE:LH) rating to Neutral and increased the price target from $270 to $300.
• Labcorp collaborates with PathAI to enhance digital pathology capabilities using the FDA-cleared AISight® Dx1 platform.
• The stock price of Labcorp reflects a positive trend, with a current price of $285.30, indicating potential growth.

Labcorp (NYSE:LH) is a prominent player in the laboratory services industry, known for its comprehensive range of diagnostic solutions. On February 24, 2026, Piper Sandler adjusted Labcorp's rating to Neutral, maintaining a hold action. At that time, the stock was priced at $285.30. Piper Sandler also increased Labcorp's price target from $270 to $300, indicating potential growth.

Labcorp's recent collaboration with PathAI is a strategic move to enhance its digital pathology capabilities. The deployment of the FDA-cleared AISight® Dx1 platform aims to improve efficiency and patient care. This cloud-based technology allows pathologists to manage slides digitally, using AI to assist in diagnostics, as highlighted by Dr. Marcia Eisenberg, Labcorp's Chief Scientific Officer.

The stock price of LH reflects a positive trend, currently at $285.30, marking an increase of $2.63 or 0.93%. During the trading day, the stock fluctuated between a low of $278.97 and a high of $289.37. Over the past year, the stock has experienced a high of $293.72 and a low of $209.38, showing its volatility.

Labcorp's market capitalization stands at approximately $23.65 billion, with a trading volume of 618,341 shares. This indicates a strong market presence and investor interest. The company's focus on integrating AI into its operations could further enhance its market position and drive future growth.